MAP
CBAY

Moody Aldrich Partners’s Cymabay Therapeutics CBAY Stock Holding History

Moody Aldrich Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-261,415
Closed -$6.17M – 243
2023
Q4 		$6.17M Sell
261,415
-64,562
-20% -$1.15M 1.11% 30
2023
Q3 		$4.86M Buy
325,977
+210,637
+183% +$2.79M 0.92% 42
2023
Q2 		$1.26M Buy
+115,340
New +$1.07M 0.25% 110

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Moody Aldrich Partners's CBAY Position: Q1 2024 in Review

Moody Aldrich Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 261,415 shares — an estimated $6.17M sold.

Moody Aldrich Partners first reported a position in CBAY in Q2 2023 and held it in 3 quarters. The position peaked at $6.17M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Moody Aldrich Partners reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 261,415 Cymabay Therapeutics shares in Q1 2024, an estimated $6.17M.
  • Moody Aldrich Partners first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 3 quarters.
  • Moody Aldrich Partners's Cymabay Therapeutics position peaked at $6.17M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Moody Aldrich Partners's 13F filing for Q1 2024, filed 30 Apr 2024.